[go: up one dir, main page]

DE60128540D1 - Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen - Google Patents

Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Info

Publication number
DE60128540D1
DE60128540D1 DE60128540T DE60128540T DE60128540D1 DE 60128540 D1 DE60128540 D1 DE 60128540D1 DE 60128540 T DE60128540 T DE 60128540T DE 60128540 T DE60128540 T DE 60128540T DE 60128540 D1 DE60128540 D1 DE 60128540D1
Authority
DE
Germany
Prior art keywords
relaxin
treatment
vascular disorders
vasodilation
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128540T
Other languages
English (en)
Other versions
DE60128540T2 (de
Inventor
Kirk P Conrad
Martyn Lewis
Elaine N Unemori
Xinfan Huang
Carol A Tozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicine And Dentistry Of Ne Us, University of
University of Pittsburgh
Corthera Inc
Original Assignee
Rutgers State University of New Jersey
University of Pittsburgh
BAS Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey, University of Pittsburgh, BAS Medical Inc filed Critical Rutgers State University of New Jersey
Application granted granted Critical
Publication of DE60128540D1 publication Critical patent/DE60128540D1/de
Publication of DE60128540T2 publication Critical patent/DE60128540T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60128540T 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen Expired - Lifetime DE60128540T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18140800P 2000-02-09 2000-02-09
US181408P 2000-02-09
US20028400P 2000-04-28 2000-04-28
US200284P 2000-04-28
US24221600P 2000-10-20 2000-10-20
US242216P 2000-10-20
PCT/US2001/004370 WO2001058468A1 (en) 2000-02-09 2001-02-09 Use of relaxin to treat diseases related to vasoconstriction

Publications (2)

Publication Number Publication Date
DE60128540D1 true DE60128540D1 (de) 2007-07-05
DE60128540T2 DE60128540T2 (de) 2008-01-31

Family

ID=27391410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128540T Expired - Lifetime DE60128540T2 (de) 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Country Status (7)

Country Link
US (2) US6723702B2 (de)
EP (1) EP1253929B1 (de)
AT (1) ATE362770T1 (de)
AU (1) AU2001236886A1 (de)
CA (1) CA2397200C (de)
DE (1) DE60128540T2 (de)
WO (1) WO2001058468A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131644T2 (de) * 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
CA2413768A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Pharmaceutical compositions for angiogenic therapy
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ITFI20030328A1 (it) * 2003-12-24 2005-06-25 Mario Bigazzi Uso della relaxina come adiuvante nella differenziazione
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CA2559745C (en) * 2004-03-19 2010-11-02 Bas Medical, Inc. Use of relaxin to increase arterial compliance
JP4764872B2 (ja) * 2004-03-30 2011-09-07 インダストリー−アカデミック コオペレイション ファウンデーション，ヨンセイ ユニバーシティ リラクシン遺伝子を含む遺伝子伝達システム及びリラクシンを用いた薬剤学的組成物
AU2005247332A1 (en) * 2004-04-30 2005-12-08 Corthera, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
EP1846443A4 (de) * 2005-01-07 2008-07-23 Glaxo Group Ltd Neuartige verwendung
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1877065A4 (de) 2005-04-12 2010-12-22 Intradigm Corp Zusammensetzung und verfahren mit rnai-therapeutika zur behandlung von krebs und anderen gefässneubildungserkrankungen
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
WO2007027168A1 (en) * 2005-08-29 2007-03-08 Carrier Corporation Compressor muffler
BRPI0714593A2 (pt) * 2006-07-25 2013-05-07 Alcon Res Ltd antagonistas de receptores da subfamÍlia 3 (edg-3, s1p3) do gene de diferenciaÇço endotelial para a prevenÇço e tratamento de doenÇas oculares, composiÇÕes compreendendo os referidos antagonistas, e usos dos mesmos
JP5291704B2 (ja) * 2007-05-11 2013-09-18 コーニング インコーポレイテッド 改良された端部支持条件を用いたアイソパイプのサグ・コントロール
PT2288373E (pt) 2008-05-16 2015-10-19 Corthera Inc Método de tratamento da dispneia associado com insuficiência cardíaca aguda
EP2278993A4 (de) * 2008-05-16 2012-09-12 Corthera Inc Verfahren zur förderung von wundheilung
CN102224420B (zh) * 2008-11-24 2014-09-17 科尔泰拉公司 先兆子痫的预测和预防
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
RU2564900C2 (ru) 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
MX2014000031A (es) * 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
CA2842395A1 (en) * 2011-08-04 2013-02-07 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013033324A2 (en) 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
RU2015105178A (ru) * 2012-07-31 2016-09-20 Новартис Аг Лечение воспаления с использованием серелаксина
US9381231B2 (en) * 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
EP4229193A4 (de) * 2020-10-15 2025-03-19 Northeastern University Manipulierte zellen für erhöhte kollagenproduktion
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
DE3236264A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur gewinnung von relaxin
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
EP0407401B1 (de) * 1988-02-26 1993-04-21 Genentech, Inc. Humanes relaxinpräparat
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO1995003822A2 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
WO1995007711A1 (en) 1993-09-14 1995-03-23 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting blood vessel blockage using a polypeptide
AU6777196A (en) * 1995-08-15 1997-03-12 Connective Therapeutics Inc. Method of promoting angiogenesis
US6251863B1 (en) * 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin

Also Published As

Publication number Publication date
EP1253929A4 (de) 2003-03-05
DE60128540T2 (de) 2008-01-31
ATE362770T1 (de) 2007-06-15
EP1253929B1 (de) 2007-05-23
HK1051001A1 (en) 2003-07-18
AU2001236886A1 (en) 2001-08-20
WO2001058468A1 (en) 2001-08-16
CA2397200A1 (en) 2001-08-16
EP1253929A1 (de) 2002-11-06
CA2397200C (en) 2010-11-23
US20020019349A1 (en) 2002-02-14
US20040266685A1 (en) 2004-12-30
US6723702B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60115842D1 (de) Ventilanordnung
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE454155T1 (de) Verwendung von drospirenon zur behandlung von hypertension
EP1274414A4 (de) Nasale verabreichung von mitteln zur behandlung von gastroparese
DK1343472T3 (da) Thixotropisk næsespray
DE60334556D1 (de) Chorionic gonadotropin zur Behandlung des chronischen Schmerzsyndroms des Beckens
DE60030107D1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
SE0004101D0 (sv) New use
SE9902597D0 (sv) New use
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
ATE283059T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von reizbarkeit
EP1854476A3 (de) Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
RU2001118219A (ru) Ингибитор ангиогенеза
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CORTHERA INC., (N. D. GES. D. STAATES DELAWARE, US

Owner name: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NE, US

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH, US